General Information of Drug (ID: DMX3O0D)

Drug Name
UFT
Synonyms Futraful; Orzel; UFUR; Tegafur + uracil; UFT + leucovorin; BMS-200604-01; Tegafur + uracil, Taiho/Bristol-Myers Squibb
Indication
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Approved [1]
Affected Organisms
Humans and other mammals
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski):
0
Molecular Weight 312.25
Logarithm of the Partition Coefficient Not Available
Rotatable Bond Count 1
Hydrogen Bond Donor Count 3
Hydrogen Bond Acceptor Count 6
ADMET Property
Elimination
Less than 20% of the administered dose of tegafur is excreted intact in the urine following the oral administration [2]
Half-life
The concentration or amount of drug in body reduced by one-half in 11 hours [3]
Metabolism
The drug is metabolized via the liver [2]
Vd
The volume of distribution (Vd) of drug is 474 L []
Chemical Identifiers
Formula
C12H13FN4O5
IUPAC Name
5-fluoro-1-(oxolan-2-yl)pyrimidine-2,4-dione;1H-pyrimidine-2,4-dione
Canonical SMILES
C1CC(OC1)N2C=C(C(=O)NC2=O)F.C1=CNC(=O)NC1=O
InChI
InChI=1S/C8H9FN2O3.C4H4N2O2/c9-5-4-11(6-2-1-3-14-6)8(13)10-7(5)12;7-3-1-2-5-4(8)6-3/h4,6H,1-3H2,(H,10,12,13);1-2H,(H2,5,6,7,8)
InChIKey
DHMYGZIEILLVNR-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
104747
CAS Number
74578-38-4
UNII
HMI5GR78FR
DrugBank ID
DB09327
TTD ID
D0Y8PT
INTEDE ID
DR1540
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 2A6 (CYP2A6)
Main DME
DEJVYAZ CP2A6_HUMAN Substrate [4]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Equilibrative nucleoside transporter 1 (SLC29A1) OTLOOZZS S29A1_HUMAN Gene/Protein Processing [5]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 Clinical pipeline report, company report or official report of Taiho Pharmaceutical.
2 UFT (uracil/tegafur) capsules_Product information
3 Comparative pharmacology of oral fluoropyrimidines: a focus on pharmacokinetics, pharmacodynamics and pharmacomodulation. Br J Cancer. 2004 Aug 16;91(4):613-7.
4 UFT Capsules (uracil-tegafur).
5 Schedule-dependent therapeutic effects of gemcitabine combined with uracil-tegafur in a human pancreatic cancer xenograft model. Pancreas. 2006 Aug;33(2):142-7. doi: 10.1097/01.mpa.0000226882.48204.26.